Trial reportBlood advances2018
Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation.
Trial report in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.Transplantation and cellular therapy · 2022Pooled it
- Subsequent malignant neoplasm among cancer survivors in the United States.Journal of cancer survivorship : research and practice · 2026Article
- Transcriptomic atlas of premalignant oral squamous cell carcinoma in an aging mouse model reveals an enhanced immune response and dysregulation of head and neck tissue stem cells.bioRxiv : the preprint server for biology · 2026Article
- Clonal hematopoiesis and risk of nonmyeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation.Journal of the National Cancer Institute · 2025Article
- Exploring the aftermath of hematopoietic cell transplantation: 18-year insights into post-transplant neoplasms.Frontiers in oncology · 2025Article
- Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era.Advances in experimental medicine and biology · 2025Review
- Benign tumors and non-melanoma skin cancers in patients with Fanconi anemia.Familial cancer · 2024Observational
- [Chinese expert consensus on the management of long-term complications after hematopoietic stem cell transplantation (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Decision analysis of allogeneic bone marrow transplantation versus immunosuppressive therapy for young adult patients with aplastic anemia.International journal of hematology · 2023Article
- Risk of Secondary Malignancies in Hematopoietic Stem Cell Transplantation Recipients: A Nationwide Population-Based Study in TaiwanBalkan medical journal · 2023Article
- Outcomes of patients with esophageal cancer after allogeneic hematopoietic stem cell transplantation.Journal of gastrointestinal oncology · 2022Article
- Definitive radiotherapy for secondary esophageal cancer after allogeneic hematopoietic stem cell transplantation.International cancer conference journal · 2021Article
- Three resected cases of esophageal carcinoma considered as being secondary solid tumors after bone marrow transplantation.Surgical case reports · 2021Article
- Esophagectomy for the patients with squamous cell carcinoma of the esophagus after allogeneic hematopoietic stem cell transplantation.International journal of clinical oncology · 2020Article
- High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation.Blood advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To characterize the outcomes of patients who developed a particular subsequent solid cancer after hematopoietic cell transplantation (HCT), age at cancer diagnosis, survival, and causes of death were compared with the respective primary cancer in the general population, using data from the national HCT registry and population-based cancer registries in Japan. Among 31 867 patients who underwent a first HCT between 1990 and 2013 and had progression-free survival at 1 year, 713 patients developed subsequent solid cancer. The median age at subsequent solid cancer diagnosis was 55 years, which was significantly younger than the 67 years for primary cancer patients in the general population (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.